文献速递细菌感染、耐药与抗菌药物

德国三级医院2012-19年甲氧苄啶/磺胺甲噁唑耐药MRSA增加的分子分析

Molecular analysis of an increase in trimethoprim/sulfamethoxazole-resistant MRSA reveals multiple introductions into a tertiary care hospital, Germany 2012-19.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

结果显示MSSA和MRSA耐药率分别波动于1.5%-7.2%和0.5%-20.2%,且耐药MRSA以主要流行CA-MRSA克隆为主,系统发育分析支持多次独立引入而非克隆传播。

要点

  • MSSA和MRSA对甲氧苄啶/磺胺甲噁唑耐药率分别最高达7.2%和20.2%。
  • 耐药MRSA多属CA-MRSA克隆,59%为ST22、ST8、ST398、ST772、ST30。
  • 系统发育分析支持耐药MRSA多次独立引入,尤其是dfrA+ ST22克隆。

核心结论

  • 甲氧苄啶/磺胺甲噁唑耐药金黄色葡萄球菌在温带地区呈上升趋势,可能部分与移民相关。

主要发现

  • 耐药更常见于门诊患者(P=0.005)、年轻患者(P<0.001)、皮肤软组织感染(仅MRSA,P=0.05)、肺科送检(仅MRSA,P=0.001)、上呼吸道(仅MSSA,P<0.001)和普外科(仅MSSA,P=0.001)。
  • 76株耐药MRSA中,59%属主要流行CA-MRSA克隆(ST22、ST8、ST398、ST772、ST30),47%携带PVL,97%为SCCmec IV/V,71%携带dfrG,28%携带dfrA。
  • 基于SNP的系统发育分析支持独立引入而非克隆扩增,尤其是来自加沙地带的dfrA+ ST22耐药MRSA。

临床怎么用

  • 建议加强对金黄色葡萄球菌甲氧苄啶/磺胺甲噁唑耐药的监测以保护抗叶酸化合物的有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Increasing spread of resistance could jeopardize the use of antifolates against MRSA infections. METHODS: We compared the prevalence of phenotypic trimethoprim/sulfamethoxazole resistance in 20 534 clinical Staphylococcus aureus isolates (19 096 MSSA and 1438 MRSA) of non-redundant patients at Heidelberg University Hospital over 8 years and performed WGS on trimethoprim/sulfamethoxazole-resistant MRSA. RESULTS: From 2012 to 2019, trimethoprim/sulfamethoxazole resistance in MSSA (674/19 096; 3.5%) ranged between 1.5% and 7.2% and in MRSA (135/1438; 9.4%) between 0.5% and 20.2%, reaching a peak in 2016 and 2018, respectively (Ptrend < 0.001). Trimethoprim/sulfamethoxazole resistance was more likely in outpatients than inpatients (P = 0.005), younger patients (P < 0.001), skin and soft tissue infections (SSTIs) (MRSA only, P = 0.05), submissions from pulmonology (MRSA only, P = 0.001), the upper respiratory tract (MSSA only, P < 0.001) and general surgery (MSSA only, P = 0.001). WGS of 76 trimethoprim/sulfamethoxazole-resistant MRSA revealed that 59% belonged to major pandemic CA-MRSA clones (ST22, ST8, ST398, ST772, ST30), 47% harboured Panton-Valentine leucocidin (PVL), 97% SCCmec IV/V, 71% dfrG and 28% dfrA. SNP-based phylogeny of trimethoprim/sulfamethoxazole-resistant MRSA core genomes favoured independent introduction over clonal expansion as the source, most prominently of dfrA+ trimethoprim/sulfamethoxazole-resistant ST22 MRSA from the Gaza Strip. CONCLUSIONS: The presented results support that trimethoprim/sulfamethoxazole-resistant S. aureus, formerly associated with SSTI from outpatients and S. aureus in the (sub)tropics, is on the rise in the temperate zone, potentially due to migration. Closer monitoring of trimethoprim/sulfamethoxazole resistance in S. aureus is recommended to safeguard the effectiveness of antifolate compounds.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Nurjadi D, Klein S, Hannesen J, et al. Molecular analysis of an increase in trimethoprim/sulfamethoxazole-resistant MRSA reveals multiple introductions into a tertiary care hospital, Germany 2012-19. J Antimicrob Chemother. 2021. PMID: 34529777. doi:10.1093/jac/dkab341

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。